Target(s)
- Bayer Aktiengesellschaft’s animal health business
Summary
Elanco Animal Health Incorporated proposes to acquire Bayer Aktiengesellschaft’s animal health business, which covers development and distribution of prescription and non-prescription products for farm and companion animals. In Australia, this includes:
- pharmaceuticals, such as parasiticides and antimicrobials and analgesics,
- specialty products, which include immunomodulators,
- nutritionals, including vitamins, feed supplements and feed additives, and
- other products including disinfectants.
Market definition
Refer to the attached Public Competition Assessment.
Competition analysis
Refer to the attached Public Competition Assessment.
Public competition assessment
Undertakings
Timeline
| Date | Event |
|---|---|
| 20/12/2019 | ACCC commenced informal review under the Informal Merger Review Process Guidelines. |
| 03/02/2020 | Closing date for submissions from interested parties. |
| 10/03/2020 | ACCC requested further information from the parties. Former provisional date for announcement of findings (12 March) delayed. |
| 09/04/2020 | ACCC received further information from the parties. |
| 22/04/2020 | ACCC is awaiting further information from the parties. Former provisional date for announcement of findings (30 April) is delayed. |
| 29/05/2020 | ACCC commenced market consultation on proposed s87B undertaking. ACCC timeline recommenced. |
| 10/06/2020 | Closing date for submissions relating to the draft proposed divestment undertaking. |
| 15/06/2020 | ACCC is awaiting information from the parties. Former provisional date for announcement of findings (18 June) is delayed. |
| 29/06/2020 | ACCC received further information from the parties. |
| 09/07/2020 | ACCC announced it would not oppose the proposed acquisition, subject to a section 87B undertaking accepted by the ACCC. |